Loading stock data…
1,894pGBX-20.00p (-1.04%)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK plc in the Healthcare sector is trading at 1,894p with a market capitalization of $75.9B. Wall Street consensus targets 2,175p (21 analysts), implying a +14.8% move over the next 12 months. The stock is currently 17% below its 52-week high of 2,282p, remaining 2.9% below its 200-day moving average. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (GBP) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | £7.99B↓ | £8.55B↓ | £8.62B↑ | £7.63B↓ | £8.41B |
| Gross Profit | £5.82B↓ | £6.29B↑ | £5.96B↑ | £5.75B↓ | £6.14B |
| Operating Income | £2.02B↓ | £2.59B↑ | £1.51B↓ | £2.29B↑ | £481.00M |
| Net Income | £1.44B↓ | £2.01B↑ | £636.00M↓ | £1.74B↑ | £435.00M |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...